Matches in Wikidata for { <http://www.wikidata.org/entity/Q90754922> ?p ?o ?g. }
Showing items 1 to 45 of
45
with 100 items per page.
- Q90754922 description "artículu científicu espublizáu n'agostu de 2018" @default.
- Q90754922 description "scientific article published on 03 August 2018" @default.
- Q90754922 description "wetenschappelijk artikel" @default.
- Q90754922 description "наукова стаття, опублікована в серпні 2018" @default.
- Q90754922 name "Roscovitine and purvalanol A effectively reverse anthracycline resistance mediated by the activity of aldo-keto reductase 1C3 (AKR1C3): A promising therapeutic target for cancer treatment" @default.
- Q90754922 name "Roscovitine and purvalanol A effectively reverse anthracycline resistance mediated by the activity of aldo-keto reductase 1C3 (AKR1C3): A promising therapeutic target for cancer treatment" @default.
- Q90754922 type Item @default.
- Q90754922 label "Roscovitine and purvalanol A effectively reverse anthracycline resistance mediated by the activity of aldo-keto reductase 1C3 (AKR1C3): A promising therapeutic target for cancer treatment" @default.
- Q90754922 label "Roscovitine and purvalanol A effectively reverse anthracycline resistance mediated by the activity of aldo-keto reductase 1C3 (AKR1C3): A promising therapeutic target for cancer treatment" @default.
- Q90754922 prefLabel "Roscovitine and purvalanol A effectively reverse anthracycline resistance mediated by the activity of aldo-keto reductase 1C3 (AKR1C3): A promising therapeutic target for cancer treatment" @default.
- Q90754922 prefLabel "Roscovitine and purvalanol A effectively reverse anthracycline resistance mediated by the activity of aldo-keto reductase 1C3 (AKR1C3): A promising therapeutic target for cancer treatment" @default.
- Q90754922 P1433 Q90754922-10533336-16F2-4517-9A0C-58F32BA8432F @default.
- Q90754922 P1476 Q90754922-E958A54F-0590-4162-AE08-FB126CC66689 @default.
- Q90754922 P2093 Q90754922-0304D424-7736-4287-B666-F841A6DE3776 @default.
- Q90754922 P2093 Q90754922-3E1BB58D-998A-4B6F-B2A7-602972DFA2C4 @default.
- Q90754922 P2093 Q90754922-915A3992-9FF2-4F55-98A8-20AC5636772E @default.
- Q90754922 P2093 Q90754922-CACE9C6D-24D8-4195-85C3-C2C480F9689B @default.
- Q90754922 P2093 Q90754922-E170078C-92E1-4BB3-BCB3-60A3A98CFF1A @default.
- Q90754922 P2093 Q90754922-FA40B4F3-ABB4-40B3-B237-C3A0E5E2DE90 @default.
- Q90754922 P2860 Q90754922-70C522FF-81E0-4D7F-84C3-7811BE1C43AD @default.
- Q90754922 P304 Q90754922-5329E591-5E1C-4F5A-899E-F8805F8779DE @default.
- Q90754922 P31 Q90754922-A9BF8B35-2164-4336-A5D0-F0D4AC83C8B0 @default.
- Q90754922 P356 Q90754922-2BBA0912-0CBD-4965-BE8E-5D7B1EECA263 @default.
- Q90754922 P478 Q90754922-1E4083B4-00EC-4C49-B0C4-29662E86E20F @default.
- Q90754922 P50 Q90754922-06575595-B414-4415-80A5-0F13F2A5BE24 @default.
- Q90754922 P577 Q90754922-B91A025B-4881-46E7-AFAB-22E59DD3631B @default.
- Q90754922 P698 Q90754922-536DBCAC-E4D5-44AA-B879-70E69C6F62D2 @default.
- Q90754922 P356 J.BCP.2018.08.001 @default.
- Q90754922 P698 30077642 @default.
- Q90754922 P1433 Q864229 @default.
- Q90754922 P1476 "Roscovitine and purvalanol A effectively reverse anthracycline resistance mediated by the activity of aldo-keto reductase 1C3 (AKR1C3): A promising therapeutic target for cancer treatment" @default.
- Q90754922 P2093 "Dagmar Louvarová" @default.
- Q90754922 P2093 "Etela Kouklíková" @default.
- Q90754922 P2093 "Eva Novotná" @default.
- Q90754922 P2093 "Michaela Flaxová" @default.
- Q90754922 P2093 "Neslihan Büküm" @default.
- Q90754922 P2093 "Vladimír Wsól" @default.
- Q90754922 P2860 Q27902293 @default.
- Q90754922 P304 "22-31" @default.
- Q90754922 P31 Q13442814 @default.
- Q90754922 P356 "10.1016/J.BCP.2018.08.001" @default.
- Q90754922 P478 "156" @default.
- Q90754922 P50 Q53818085 @default.
- Q90754922 P577 "2018-08-03T00:00:00Z" @default.
- Q90754922 P698 "30077642" @default.